| For: | Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003; 9(12): 2681-2685 [PMID: 14669312 DOI: 10.3748/wjg.v9.i12.2681] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v9/i12/2681.htm |
| Number | Citing Articles |
| 1 |
Dermot Gleeson, Michael A Heneghan. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60(12) doi: 10.1136/gut.2010.235259
|
| 2 |
Albert J. Czaja. The Overlap Syndromes of Autoimmune Hepatitis. Digestive Diseases and Sciences 2012; doi: 10.1007/s10620-012-2367-1
|
| 3 |
Michael Lin, S. Chris Pappas. Managing Gastrointestinal Complications of Diabetes. 2017; doi: 10.1007/978-3-319-48662-8_7
|
| 4 |
Albert J Czaja. Current and future treatments of autoimmune hepatitis. Expert Review of Gastroenterology & Hepatology 2009; 3(3) doi: 10.1586/egh.09.15
|
| 5 |
Jia Kang, Tong Zhang, Hongyue Wang, Caihong Shi, Xiangrong Zhang. Chitosan nanoparticles loaded with velvet antler polypeptides for intervention in autoimmune hepatitis. Food Bioscience 2024; 62 doi: 10.1016/j.fbio.2024.105102
|
| 6 |
Albert J. Czaja. Diagnosis and Management of Autoimmune Hepatitis. Clinics in Liver Disease 2015; 19(1) doi: 10.1016/j.cld.2014.09.004
|
| 7 |
|
| 8 |
Ja Kyung Kim. Treatment of Autoimmune Hepatitis. The Korean Journal of Gastroenterology 2023; 81(2) doi: 10.4166/kjg.2023.011
|
| 9 |
John M. Vierling. Diagnosis and Treatment of Autoimmune Hepatitis. Current Gastroenterology Reports 2012; 14(1) doi: 10.1007/s11894-011-0236-2
|
| 10 |
Michael Yulong Wu, Rhian Aghajani, Sophie Timmins, Anna Di Bartolomeo, Rachael Jacob, Robert Ng, Jacob George, Harry Crane, Cameron Gofton, Ned Snyder. A Rare, Atypical Presentation of Decompensated Cirrhosis: Isolated Transudative Hepatic Chylothorax Without Ascites. Case Reports in Hepatology 2025; 2025(1) doi: 10.1155/crhe/5596329
|
| 11 |
Albert J Czaja. Drug choices in autoimmune hepatitis: Part A – steroids. Expert Review of Gastroenterology & Hepatology 2012; 6(5) doi: 10.1586/egh.12.40
|
| 12 |
Silja Steinmann, Ansgar W. Lohse. Treatment of autoimmune hepatitis: Budesonide does not solve our problems. Hepatology 2023; 77(4) doi: 10.1097/HEP.0000000000000183
|
| 13 |
Ignasi Olivas, Marina Cobreros, María-Carlota Londoño, Álvaro Díaz-González. Budesonide in the first line treatment of patients with autoimmune hepatitis. Gastroenterología y Hepatología (English Edition) 2022; 45(7) doi: 10.1016/j.gastre.2021.11.003
|
| 14 |
Thejus Jayakrishnan, Meera Babu, Steven Goodnow, Brent Hardman. Budesonide-Induced Hyperosmolar Hyperglycemic State Following Transjugular Intrahepatic Portosystemic Shunt. AACE Clinical Case Reports 2020; 6(5) doi: 10.4158/ACCR-2020-0216
|
| 15 |
A. J. Czaja. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Alimentary Pharmacology & Therapeutics 2013; 38(4) doi: 10.1111/apt.12381
|
| 16 |
Iliana Doycheva, Kymberly D. Watt, Aliya F. Gulamhusein. Autoimmune hepatitis: Current and future therapeutic options. Liver International 2019; 39(6) doi: 10.1111/liv.14062
|
| 17 |
Nancy S. Reau, Craig S. Lammert, Ethan M. Weinberg. Autoimmune hepatitis: Current and future therapies. Hepatology Communications 2024; 8(6) doi: 10.1097/HC9.0000000000000458
|
| 18 |
Saeed Mohammad. Budesonide as first-line therapy for non-cirrhotic autoimmune hepatitis in children: a decision analysis. Scandinavian Journal of Gastroenterology 2016; 51(6) doi: 10.3109/00365521.2015.1130166
|
| 19 |
Marcial Sebode, Heike Bantel, Ulrich Baumann, Philip Bufler, Münevver Demir, Leona Dold, Verena Keitel-Anselmino, Reinhild Klein, Andreas E. Kremer, Petra L. Jansen, Michael Melter, Peter Schirmacher, Christoph Schramm, Martina Sterneck, Christian P. Strassburg, Christina Weiler-Normann, Ansgar W. Lohse. Update der S3-Leitlinie „Seltene Lebererkrankungen (LeiSe LebEr) – Autoimmune Lebererkrankungen von der Pädiatrie bis zum Erwachsenenalter“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – Living guideline. Zeitschrift für Gastroenterologie 2026; 64(05) doi: 10.1055/a-2769-2475
|
| 20 |
|
| 21 |
Raj A Shah, Kris V Kowdley. Current and potential treatments for primary biliary cholangitis. The Lancet Gastroenterology & Hepatology 2020; 5(3) doi: 10.1016/S2468-1253(19)30343-7
|
| 22 |
AbdulrahmanA Aljumah, Badr Al Jarallah, Ali Albenmousa, Abdullah Al Khathlan, Adnan Al Zanbagi, Mohammed Al Quaiz, Bandar Al-Judaibi, Khalid Nabrawi, Waleed Al Hamoudi, Mohammed Alghamdi, Hind Fallatah. The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis. Saudi Journal of Gastroenterology 2018; 24(7) doi: 10.4103/sjg.SJG_159_18
|
| 23 |
Albert J Czaja. Current and prospective pharmacotherapy for autoimmune hepatitis. Expert Opinion on Pharmacotherapy 2014; 15(12) doi: 10.1517/14656566.2014.931938
|
| 24 |
Ignasi Olivas, Marina Cobreros, María-Carlota Londoño, Álvaro Díaz-González. Budesonide in the first line treatment of patients with autoimmune hepatitis. Gastroenterología y Hepatología 2022; 45(7) doi: 10.1016/j.gastrohep.2021.11.012
|
| 25 |
A. D. YEOMAN, M. S. LONGHI, M. A. HENEGHAN. Review article: the modern management of autoimmune hepatitis. Alimentary Pharmacology & Therapeutics 2010; 31(8) doi: 10.1111/j.1365-2036.2010.04241.x
|
| 26 |
C. Corpechot, O. Chazouillères. Hépatites auto-immunes : actualités diagnostiques et thérapeutiques. La Revue de Médecine Interne 2010; 31(9) doi: 10.1016/j.revmed.2009.05.015
|
| 27 |
John M. Vierling. Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management. Clinical Gastroenterology and Hepatology 2015; 13(12) doi: 10.1016/j.cgh.2015.08.012
|
| 28 |
Farhad Sahebjam, John M. Vierling. Autoimmune hepatitis. Frontiers of Medicine 2015; 9(2) doi: 10.1007/s11684-015-0386-y
|
| 29 |
Andrew S. deLemos. Diagnosis and Management of Autoimmune Hepatitis. 2020; doi: 10.1007/978-3-030-33628-8_5
|
| 30 |
Albert J Czaja. Clinical Features, Differential Diagnosis and Treatment of Autoimmune Hepatitis in the Elderly. Drugs & Aging 2008; 25(3) doi: 10.2165/00002512-200825030-00005
|
| 31 |
Eve A. Roberts. Autoimmune hepatitis from the paediatric perspective. Liver International 2011; 31(10) doi: 10.1111/j.1478-3231.2011.02603.x
|
| 32 |
V. Selvarajah, A. J. Montano‐Loza, A. J. Czaja. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Alimentary Pharmacology & Therapeutics 2012; 36(8) doi: 10.1111/apt.12042
|
| 33 |
Teru Kumagi, Khalid Alswat, Gideon M. Hirschfield, Jenny Heathcote. New insights into autoimmune liver diseases. Hepatology Research 2008; 38(8) doi: 10.1111/j.1872-034X.2008.00366.x
|
| 34 |
Aldo J Montano Loza, Albert J Czaja. Current therapy for autoimmune hepatitis. Nature Clinical Practice Gastroenterology & Hepatology 2007; 4(4) doi: 10.1038/ncpgasthep0768
|
| 35 |
Albert J Czaja, Yusuf Bayraktar. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World Journal of Gastroenterology 2009; 15(19): 2314-2328 doi: 10.3748/wjg.15.2314
|
| 36 |
Albert J Czaja. Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. Gut and Liver 2016; 10(2) doi: 10.5009/gnl15352
|
| 37 |
Andréanne N. Zizzo, Pamela L. Valentino, Prakesh S. Shah, Binita M. Kamath. Second‐line Agents in Pediatric Patients With Autoimmune Hepatitis. Journal of Pediatric Gastroenterology and Nutrition 2017; 65(1) doi: 10.1097/MPG.0000000000001530
|
| 38 |
Cara L. Mack, David Adams, David N. Assis, Nanda Kerkar, Michael P. Manns, Marlyn J. Mayo, John M. Vierling, Mouaz Alsawas, Mohammad H. Murad, Albert J. Czaja. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 2020; 72(2) doi: 10.1002/hep.31065
|
| 39 |
Natanie J. Anilovich. Oral budesonide is an effective alternative to prednisone for treatment of autoimmune hepatitis. Clinical Research In Practice: The Journal of Team Hippocrates 2021; 7(2) doi: 10.22237/crp/1622160960
|
| 40 |
Dorothy Liu, William M. W. Bonwick, Priya Sumithran, Josephine A. Grace, Marie Sinclair. Budesonide in Liver Immunology: A Therapeutic Opportunity in Liver Transplantation. Current Transplantation Reports 2024; 11(4) doi: 10.1007/s40472-024-00441-9
|
| 41 |
Syed Rizvi, Samer Gawrieh. Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management. Drugs & Aging 2018; 35(7) doi: 10.1007/s40266-018-0556-0
|
| 42 |
Lydia A. Mercado, Fernando Gil-Lopez, Razvan M. Chirila, Denise M. Harnois. Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview. Diagnostics 2024; 14(4) doi: 10.3390/diagnostics14040382
|
| 43 |
T. O. Lankisch, C. P. Strassburg, M. P. Manns. Autoimmune Liver Disease. Falk Symposium 2005; 142 doi: 10.1007/1-4020-2914-4_18
|
| 44 |
|
| 45 |
Albert J. Czaja. Evolving paradigm of treatment for autoimmune hepatitis. Expert Review of Clinical Immunology 2017; 13(8) doi: 10.1080/1744666X.2017.1319764
|
| 46 |
Agnes Nuo Han, Beatrice Rae Han, Tao Zhang, Tycho Heimbach. Hepatic Impairment Physiologically Based Pharmacokinetic Model Development: Current Challenges. Current Pharmacology Reports 2021; 7(6) doi: 10.1007/s40495-021-00266-5
|
| 47 |
Luigi Muratori, Paolo Muratori, Alessandro Granito, Giorgios Pappas, Fabio Cassani, Marco Lenzi. Current topics in autoimmune hepatitis. Digestive and Liver Disease 2010; 42(11) doi: 10.1016/j.dld.2010.05.019
|
| 48 |
Paul A. Schmeltzer. Diagnosis and Management of Autoimmune Hepatitis. 2020; doi: 10.1007/978-3-030-33628-8_6
|
| 49 |
Albert J. Czaja, Michael P. Manns. Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis. Gastroenterology 2010; 139(1) doi: 10.1053/j.gastro.2010.04.053
|
| 50 |
Albert J. Czaja. Advances in the Current Treatment of Autoimmune Hepatitis. Digestive Diseases and Sciences 2012; 57(8) doi: 10.1007/s10620-012-2151-2
|
| 51 |
EASL Clinical Practice Guidelines: Autoimmune hepatitis. Journal of Hepatology 2015; 63(4) doi: 10.1016/j.jhep.2015.06.030
|
| 52 |
O. Chazouillères. Un cas d’hépatite auto-immune. Gastroentérologie Clinique et Biologique 2009; 33(10-11) doi: 10.1016/j.gcb.2009.07.015
|
| 53 |
Brian H Le, Ghauri Aggarwal, Carol Douglas, Michael Green, Amanda Nicoll, Sam Ahmedzai. Oxycodone/naloxone prolonged‐release tablets in patients with moderate‐to‐severe, chronic cancer pain: Challenges in the context of hepatic impairment. Asia-Pacific Journal of Clinical Oncology 2022; 18(1) doi: 10.1111/ajco.13561
|
| 54 |
Nahum Méndez-Sánchez, Carlos E. Coronel-Castillo, Ana L. Ordoñez-Vázquez. Current Therapies for Cholestatic Diseases. Biomedicines 2023; 11(6) doi: 10.3390/biomedicines11061713
|
| 55 |
S3-Leitlinie „Seltene Lebererkrankungen (LeiSe LebEr) – Autoimmune Lebererkrankungen von der Pädiatrie bis zum Erwachsenenalter“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Zeitschrift für Gastroenterologie 2025; 63(06) doi: 10.1055/a-2558-5204
|
| 56 |
Charles Ronsin, Pierre Braud, Christine Kandel-Aznar, Amaury Dujardin, Clémence Petit, David Larmet, Claire Garandeau, Clément Deltombe, Alice Le Clech, Claire Leman, Gilles Blancho, Juliet Schurder, Grégoire Couvrat-Desvergnes, Simon Ville. Clinical Presentation, Pathological Spectrum, and Outcomes of Alcoholic Cirrhosis-Related Immunoglobulin A Nephropathy. Kidney International Reports 2024; 9(5) doi: 10.1016/j.ekir.2024.02.1397
|
| 57 |
Albert J. Czaja, Herschel A. Carpenter. Autoimmune Hepatitis Overlap Syndromes and Liver Pathology. Gastroenterology Clinics of North America 2017; 46(2) doi: 10.1016/j.gtc.2017.01.008
|